Complete Trisomy 21 Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
As part of an effort to identify genes potentially involved in the Down Syndrome pathogenesis, in this paper we report the identification and characterization of a new human gene (named SH3BGRL), which shows a high homology to the SH3BGR gene, previously mapped to the Down Syndrome region of chromosome 21.
|
9642120 |
1998 |
Down Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
As part of an effort to identify genes potentially involved in the Down Syndrome pathogenesis, in this paper we report the identification and characterization of a new human gene (named SH3BGRL), which shows a high homology to the SH3BGR gene, previously mapped to the Down Syndrome region of chromosome 21.
|
9642120 |
1998 |
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thus, our results demonstrated that SH3BGRL is a novel crucial player in AML progression and could be both a potential diagnostic and prognostic marker.
|
28679293 |
2018 |
Leukemogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Xenograft assays further confirmed the suppressive role of SH3BGRL in leukemogenesis.
|
28679293 |
2018 |
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using a human database, increased levels of INTS7 and decreased levels of SH3BGRL were found to be associated with the aggressiveness of PCa.
|
31243108 |
2019 |
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The ERBB2+ GC with RARA amplification demonstrated better prognosis than those without RARA amplification, while overexpression of NRG2 and SH3BGRL correlated with poor prognosis in ERBB2+ GC.
|
30123134 |
2018 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results uncover an evolutionarily controversial role of SH3BGRL in driving tumor metastasis through c-Src activation, and suggests that hSH3BGRL mutation status could be relevant to cancer diagnosis and therapy.
|
26455318 |
2016 |
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our results uncover an evolutionarily controversial role of SH3BGRL in driving tumor metastasis through c-Src activation, and suggests that hSH3BGRL mutation status could be relevant to cancer diagnosis and therapy.
|
26455318 |
2016 |
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
SH3-domain-binding glutamic acid-rich protein-like protein (SH3BGRL), a downstream effector of PRL-3, plays a tumor suppressive role in solid tumors, but it remains elusive in AML.
|
28679293 |
2018 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results uncover an evolutionarily controversial role of SH3BGRL in driving tumor metastasis through c-Src activation, and suggests that hSH3BGRL mutation status could be relevant to cancer diagnosis and therapy.
|
26455318 |
2016 |
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using a human database, increased levels of INTS7 and decreased levels of SH3BGRL were found to be associated with the aggressiveness of PCa.
|
31243108 |
2019 |
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results uncover an evolutionarily controversial role of SH3BGRL in driving tumor metastasis through c-Src activation, and suggests that hSH3BGRL mutation status could be relevant to cancer diagnosis and therapy.
|
26455318 |
2016 |
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The ERBB2+ GC with RARA amplification demonstrated better prognosis than those without RARA amplification, while overexpression of NRG2 and SH3BGRL correlated with poor prognosis in ERBB2+ GC.
|
30123134 |
2018 |